A retrospective review of pediatric patients treated for psoriasis with systemic agents provides much needed insight about the safety and tolerability of these medications.
Treatments for Plaque Psoriasis
Survey highlights the challenges of controlling psoriasis flares.
Experts from around the world will gather in London at the Psoriasis from Gene to Clinic Congress to present and discuss the most current developments in the understanding of psoriasis and the evidence that will steer future clinical decision making. Watch here for highlights.
The American College of Rheumatology annual meeting wrapped this month in San Diego. Results from long-awaited safety trials show promising new treatments.
Switching from originator to biosimilar shows no significant impact on drug survival in plaque psoriasis, but outcomes differ, researchers report.
A pediatric dermatologist addresses important differences in children with psoriasis, versus adults.
The IL-23 inhibitor risankizumab was superior to ustekinumab in a phase two trial of adult patients with moderate-to-severe chronic plaque psoriasis, researchers report. (©FreeBirdPhotos/Shutterstock.com)
New research offers strong evidence that vascular inflammation and risk of having a major adverse cardiovascular event increases with psoriasis duration.
Of several biologic agents that women of reproductive age can choose from to treat and manage psoriasis, not all have the same safety profile during pregnancy and lactation periods.
Metabolomics could provide new statistical methods to help monitor psoriasis disease and progression.